Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study

H. C. Wagenaar, S. Pecorelli, I. Vergote, D. Curran, D. J Th Wagener, A. Kobierska, G. Bolis, W. Ten Bokkel-Huinink, A. J. Lacave, C. Madronal, M. Forni, C. F. De Oliveira, C. Mangioni, M. A. Nooij, A. Goupil, P. Kerbrat, Ch Marth, S. Tumolo, M. G. Herben, F. Zanaboni & 1 others J. B. Vermorken

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalEuropean Journal of Gynaecological Oncology
Volume22
Issue number3
Publication statusPublished - 2001

Fingerprint

Fallopian Tubes
Doxorubicin
Cyclophosphamide
Cisplatin
Carcinoma
Neoplasms
Adenocarcinoma
Survival
Alopecia
Combination Drug Therapy
Nausea
Vomiting

Keywords

  • Adriamycin
  • Chemotherapy
  • Cisplatin
  • Cyclophosphamide
  • Fallopian tube carcinoma
  • Phase II trial

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Wagenaar, H. C., Pecorelli, S., Vergote, I., Curran, D., Wagener, D. J. T., Kobierska, A., ... Vermorken, J. B. (2001). Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study. European Journal of Gynaecological Oncology, 22(3), 187-193.

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study. / Wagenaar, H. C.; Pecorelli, S.; Vergote, I.; Curran, D.; Wagener, D. J Th; Kobierska, A.; Bolis, G.; Ten Bokkel-Huinink, W.; Lacave, A. J.; Madronal, C.; Forni, M.; De Oliveira, C. F.; Mangioni, C.; Nooij, M. A.; Goupil, A.; Kerbrat, P.; Marth, Ch; Tumolo, S.; Herben, M. G.; Zanaboni, F.; Vermorken, J. B.

In: European Journal of Gynaecological Oncology, Vol. 22, No. 3, 2001, p. 187-193.

Research output: Contribution to journalArticle

Wagenaar, HC, Pecorelli, S, Vergote, I, Curran, D, Wagener, DJT, Kobierska, A, Bolis, G, Ten Bokkel-Huinink, W, Lacave, AJ, Madronal, C, Forni, M, De Oliveira, CF, Mangioni, C, Nooij, MA, Goupil, A, Kerbrat, P, Marth, C, Tumolo, S, Herben, MG, Zanaboni, F & Vermorken, JB 2001, 'Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study', European Journal of Gynaecological Oncology, vol. 22, no. 3, pp. 187-193.
Wagenaar, H. C. ; Pecorelli, S. ; Vergote, I. ; Curran, D. ; Wagener, D. J Th ; Kobierska, A. ; Bolis, G. ; Ten Bokkel-Huinink, W. ; Lacave, A. J. ; Madronal, C. ; Forni, M. ; De Oliveira, C. F. ; Mangioni, C. ; Nooij, M. A. ; Goupil, A. ; Kerbrat, P. ; Marth, Ch ; Tumolo, S. ; Herben, M. G. ; Zanaboni, F. ; Vermorken, J. B. / Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study. In: European Journal of Gynaecological Oncology. 2001 ; Vol. 22, No. 3. pp. 187-193.
@article{95fda4463b064f5280b11a97e16e6575,
title = "Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study",
abstract = "Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67{\%}, 95{\%} confidence limits: 45-84{\%}). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95{\%} confidence limits were 73{\%} (54-92{\%}), 25{\%} (4-46{\%}) and 19{\%} (0-38{\%}), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.",
keywords = "Adriamycin, Chemotherapy, Cisplatin, Cyclophosphamide, Fallopian tube carcinoma, Phase II trial",
author = "Wagenaar, {H. C.} and S. Pecorelli and I. Vergote and D. Curran and Wagener, {D. J Th} and A. Kobierska and G. Bolis and {Ten Bokkel-Huinink}, W. and Lacave, {A. J.} and C. Madronal and M. Forni and {De Oliveira}, {C. F.} and C. Mangioni and Nooij, {M. A.} and A. Goupil and P. Kerbrat and Ch Marth and S. Tumolo and Herben, {M. G.} and F. Zanaboni and Vermorken, {J. B.}",
year = "2001",
language = "English",
volume = "22",
pages = "187--193",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "3",

}

TY - JOUR

T1 - Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma. An EORTC Gynecological Cancer Group Study

AU - Wagenaar, H. C.

AU - Pecorelli, S.

AU - Vergote, I.

AU - Curran, D.

AU - Wagener, D. J Th

AU - Kobierska, A.

AU - Bolis, G.

AU - Ten Bokkel-Huinink, W.

AU - Lacave, A. J.

AU - Madronal, C.

AU - Forni, M.

AU - De Oliveira, C. F.

AU - Mangioni, C.

AU - Nooij, M. A.

AU - Goupil, A.

AU - Kerbrat, P.

AU - Marth, Ch

AU - Tumolo, S.

AU - Herben, M. G.

AU - Zanaboni, F.

AU - Vermorken, J. B.

PY - 2001

Y1 - 2001

N2 - Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.

AB - Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.

KW - Adriamycin

KW - Chemotherapy

KW - Cisplatin

KW - Cyclophosphamide

KW - Fallopian tube carcinoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0034892530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034892530&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 187

EP - 193

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 3

ER -